Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial details imported from ClinicalTrials.gov
For full trial details, please see the original record at
https://clinicaltrials.gov/ct2/show/NCT05475925
Registration number
NCT05475925
Ethics application status
Date submitted
21/07/2022
Date registered
27/07/2022
Date last updated
27/10/2023
Titles & IDs
Public title
A Study of DR-01 in Subjects With Large Granular Lymphocytic Leukemia or Cytotoxic Lymphomas
Query!
Scientific title
A Multicenter, Open-Label, First-In-Human, Multiple Expansion Cohort, Phase 1/2 Study to Evaluate the Safety and Efficacy of DR-01 in Adult Subjects With Large Granular Lymphocytic Leukemia or Cytotoxic Lymphomas
Query!
Secondary ID [1]
0
0
DR-01-ONC-001
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
LGLL - Large Granular Lymphocytic Leukemia
0
0
Query!
Primary Cutaneous T-Cell Lymphoma - Category
0
0
Query!
Primary Cutaneous CD8-Positive Aggressive Epidermotropic T-Cell Lymphoma
0
0
Query!
Hepatosplenic T-cell Lymphoma
0
0
Query!
Subcutaneous Panniculitis-Like T-Cell Lymphoma
0
0
Query!
Aggressive NK Cell Leukemia
0
0
Query!
Systemic EBV1 T-cell Lymphoma, if CD8 Positive
0
0
Query!
Hydroa Vacciniforme-Like Lymphoproliferative Disorder
0
0
Query!
Extranodal NK/T Cell Lymphoma, Nasal Type
0
0
Query!
Enteropathy-Associated T-Cell Lymphoma
0
0
Query!
Monomorphic Epitheliotropic Intestinal T-Cell Lymphoma
0
0
Query!
Indolent Chronic Lymphoproliferative Disorder (CLPD) (CD8+ or NK Derived) of the GI Tract
0
0
Query!
Other CD8+/NK Cell Driven Lymphoma Not Listed Above
0
0
Query!
Condition category
Condition code
Cancer
0
0
0
0
Query!
Lymphoma (non Hodgkin's lymphoma) - High grade lymphoma
Query!
Cancer
0
0
0
0
Query!
Lymphoma (non Hodgkin's lymphoma) - Low grade lymphoma
Query!
Cancer
0
0
0
0
Query!
Leukaemia - Acute leukaemia
Query!
Cancer
0
0
0
0
Query!
Leukaemia - Chronic leukaemia
Query!
Cancer
0
0
0
0
Query!
Children's - Leukaemia & Lymphoma
Query!
Cardiovascular
0
0
0
0
Query!
Diseases of the vasculature and circulation including the lymphatic system
Query!
Inflammatory and Immune System
0
0
0
0
Query!
Other inflammatory or immune system disorders
Query!
Skin
0
0
0
0
Query!
Other skin conditions
Query!
Mental Health
0
0
0
0
Query!
Other mental health disorders
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Treatment: Drugs - DR-01
Experimental: Part A Dose Escalation 1 mg/kg of DR-01 - Subjects in this arm will initially receive 1 mg/kg at either the Primary regimen (bi-weekly dosing for fist month), Secondary regimen (doses at Days 1, 8, 15, 29 during first month), or Tertiary regimen (dosing days 1-5, 15, 29 during first month), followed by monthly dosing (up to 6 mg/kg) thereafter for up to 25 cycles total.
Experimental: Part A Dose Escalation 3 mg/kg of DR-01 - Subjects in this arm will initially receive 3 mg/kg at either the Primary regimen (bi-weekly dosing for fist month), Secondary regimen (doses at Days 1, 8, 15, 29 during first month), or Tertiary regimen (dosing days 1-5, 15, 29 during first month), followed by monthly dosing (up to 10 mg/kg) thereafter for up to 25 cycles total.
Experimental: Part A Dose Escalation 6 mg/kg of DR-01 - Subjects in this arm will initially receive 6 mg/kg at either the Primary regimen (bi-weekly dosing for fist month), Secondary regimen (doses at Days 1, 8, 15, 29 during first month), or Tertiary regimen (dosing days 1-5, 15, 29 during first month), followed by monthly dosing (up to 10 mg/kg) thereafter for up to 25 cycles total.
Experimental: Part A Dose Escalation 10 mg/kg of DR-01 - Subjects in this arm will initially receive 10 mg/kg at either the Primary regimen (bi-weekly dosing for fist month), Secondary regimen (doses at Days 1, 8, 15, 29 during first month), or Tertiary regimen (dosing days 1-5, 15, 29 during first month), followed by monthly dosing (up to 10 mg/kg) thereafter for up to 25 cycles total.
Experimental: Part A Dose De-escalation 0.3 to <1 mg/kg of DR-01 - This cohort would only be triggered should a DLT occur at Dose Level 1 or if recommended by the Safety Review Committee. Subjects in this arm would initially receive 0.3 to <1 mg/kg at either the Primary regimen (bi-weekly dosing for fist month), Secondary regimen (doses at Days 1, 8, 15, 29 during first month), or Tertiary regimen (dosing days 1-5, 15, 29 during first month), followed by monthly dosing (up to 3 mg/kg) thereafter for up to 25 cycles total.
Experimental: Part B Dose Expansion (Cohort B1) Optimized Dose/Regimen of DR-01 - Subjects in this arm will receive the pharmacologically optimized dose/regimen for LGL leukemia subjects determined in Part A. Depending on the selected dose/regimen, subjects will receive target dose at either the Primary regimen (bi-weekly dosing for fist month), Secondary regimen (doses at Days 1, 8, 15, 29 during first month), or Tertiary regimen (dosing days 1-5, 15, 29 during first month), followed by monthly dosing thereafter for up to 25 doses total.
Experimental: Part B Dose Expansion (Cohort B2) Optimized Dose/Regimen of DR-01 - Subjects in this arm will receive the pharmacologically optimized dose/regimen for cytotoxic lymphoma subjects determined in Part A. Depending on the selected dose/regimen, subjects will receive target dose at either the Primary regimen (bi-weekly dosing for fist month), Secondary regimen (doses at Days 1, 8, 15, 29 during first month), or Tertiary regimen (dosing days 1-5, 15, 29 during first month), followed by monthly dosing thereafter for up to 25 doses total.
Treatment: Drugs: DR-01
DR-01 is a non-fucosylated, human immunoglobulin G1 (IgG1) monoclonal antibody.
Query!
Intervention code [1]
0
0
Treatment: Drugs
Query!
Comparator / control treatment
Query!
Control group
Query!
Outcomes
Primary outcome [1]
0
0
Part A: Safety and Tolerability. To determine the incidence and severity of adverse events as assessed by CTCAE v5.0.
Query!
Assessment method [1]
0
0
Query!
Timepoint [1]
0
0
Up to 25 months
Query!
Primary outcome [2]
0
0
Part A: Safety and Tolerability. To determine the incidence and severity of dose limiting toxicities (DLTs) as defined by protocol specified DLT criteria.
Query!
Assessment method [2]
0
0
Query!
Timepoint [2]
0
0
During First 28 days (Cycle 1)
Query!
Primary outcome [3]
0
0
Part A: To determine potential pharmacologically optimized dose/regimen for DR-01 in LGL leukemia and cytotoxic lymphoma populations as determined using an integrated assessment of efficacy, safety, PK/PD, and exposure-response relationships.
Query!
Assessment method [3]
0
0
Query!
Timepoint [3]
0
0
Up to 6 months
Query!
Primary outcome [4]
0
0
Part B: Overall Response Rate (ORR), defined as the proportion of subjects with Complete Response (CR) or Partial Response (PR) based on disease-specific response criteria.
Query!
Assessment method [4]
0
0
Query!
Timepoint [4]
0
0
Up to 24 months
Query!
Eligibility
Key inclusion criteria
Inclusion Criteria (All Subjects):
1. =18 years of age.
2. Able to understand and comply with protocol-required study procedures and voluntarily
sign a written informed consent document.
3. Sufficient key organ performance and coagulation.
4. Female subjects of childbearing potential (postmenarcheal, has an intact uterus and at
least one ovary, and is <1 year postmenopausal) must agree to use a highly effective
method of contraception from enrollment through at least 12 months after last dose of
DR-01.
5. Male subjects must agree to use acceptable effective method(s) of contraception.
Subjects with LGLL must also meet inclusion criteria 6 and 7.
6. Must have discontinued at least one prior line of systemic therapy.
7. Additional immunophenotypic criteria must be met.
Disease-specific Inclusion Criteria (Cytotoxic Lymphomas):
Subjects with cytotoxic lymphomas must also meet inclusion criteria 8,9, and 10.
8. Subjects must have failed at least two prior systemic regimens.
9. Availability of post-progression tissue sample or willingness to consent to a baseline
biopsy.
10. Histologically confirmed diagnosis of a cytotoxic lymphoma by a hematopathologist
(according to the WHO 2016 classification [Swerdlow 2016]).
11. For Part A only, evaluable disease is acceptable.
12. For Part B2 only:
Subjects must have radiographically measurable disease to be assessed by Lugano criteria.
Subjects with primary cutaneous variants must have at least 1 measurable lesion that is
evaluable using the Olsen criteria (Olsen 2021) or leukemic involvement that can be
evaluated using a modified TPLL response criteria (Staber 2019).
Subjects with hepatosplenic disease or other variants that do not have measurable disease
by Lugano criteria (Cheson 2014) may be eligible upon discussion with the Medical Monitor
if they have identifiable leukemic involvement in BM or peripheral blood (meeting the CD8+
cytotoxic phenotype definition) that can be evaluated for response using a modified TPLL
response criteria (Staber 2019), or skin involvement that can be evaluated using Olsen
criteria (Olsen 2021).
Query!
Minimum age
18
Years
Query!
Query!
Maximum age
No limit
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
Disease-specific Exclusion Criteria; LGLL and ANKL:
1. A reactive LGL lymphocytosis to a viral infection or LGL associated with
myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML).
The following exclusion criteria apply to all subjects:
2. Active systemic infection or severe localized infection requiring systemic
antibiotics, antivirals or antifungals.
3. Active or suspected malignant central nervous system involvement.
4. Life-threatening, severe complications of malignancy (e.g., uncontrolled bleeding,
pneumonia with hypoxia or shock, and/or disseminated intravascular coagulation).
5. Active known second malignancy.
6. Infection with human immunodeficiency virus (HIV) type 1 or 2 (HIV-1 or HIV-2).
7. Hepatitis B infection (hepatitis B virus surface antigen [HBsAg] positive), or
hepatitis C (hepatitis C virus [HCV] antibody positive, confirmed by HCV ribonucleic
acid). Subjects with HCV with undetectable virus after treatment are eligible.
8. History of clinically significant cardiac disease or congestive heart failure greater
than New York Heart Association (NYHA) Class II.
9. Use of systemic corticosteroids (e.g., >5 mg/day prednisone or equivalent for subjects
with LGL leukemia (subjects on 20 mg prednisone or equivalent to treat LGL leukemia
must be weaned within 28 days post C1D1 to 5 mg) and >10 mg/day prednisone or
equivalent for subjects with cytotoxic lymphoma) within 15 days (except for
prophylaxis for radiodiagnostic contrast reactions), or other non-biological
immunosuppressive drugs within 15 days, prior to C1D1. Patients on stable prednisone
=10 mg for documented rheumatologic/autoimmune conditions are exempted from this
requirement.
10. Any condition requiring hormonal therapy (except for contraception, hormone
replacement therapy and hormonal prophylaxis for a prior malignancy).
11. Any other medical or psychiatric condition, or laboratory abnormality that would
increase the risk associated with study participation, in the opinion of the
Investigator or Medical Monitor.
12. Toxicities from previous anticancer therapies must have resolved to baseline levels or
to Grade 1 (except for alopecia, peripheral neuropathy, or hematologic parameters
meeting inclusion criteria).
13. Autologous HSCT within 40 days of C1D1, allogeneic HSCT within 90 days
14. Any immunosuppressive therapy for GVHD for subjects who are post allogeneic HSCT.
15. Major surgery within 28 days of C1D1 (requires more than local anesthesia or plexus
blockade).
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
Non-randomised trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Open (masking not used)
Query!
Who is / are masked / blinded?
Query!
Query!
Query!
Query!
Intervention assignment
Other
Query!
Other design features
Query!
Phase
Phase 1/Phase 2
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Recruiting
Query!
Data analysis
Query!
Reason for early stopping/withdrawal
Query!
Other reasons
Query!
Date of first participant enrolment
Anticipated
Query!
Actual
13/07/2022
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
1/12/2025
Query!
Actual
Query!
Sample size
Target
69
Query!
Accrual to date
Query!
Final
Query!
Recruitment in Australia
Recruitment state(s)
VIC,WA
Query!
Recruitment hospital [1]
0
0
Dren Investigational Site - Richmond
Query!
Recruitment hospital [2]
0
0
Dren Investigational Site - Nedlands
Query!
Recruitment postcode(s) [1]
0
0
3121 - Richmond
Query!
Recruitment postcode(s) [2]
0
0
6009 - Nedlands
Query!
Recruitment outside Australia
Country [1]
0
0
United States of America
Query!
State/province [1]
0
0
Alabama
Query!
Country [2]
0
0
United States of America
Query!
State/province [2]
0
0
Arizona
Query!
Country [3]
0
0
United States of America
Query!
State/province [3]
0
0
California
Query!
Country [4]
0
0
United States of America
Query!
State/province [4]
0
0
Florida
Query!
Country [5]
0
0
United States of America
Query!
State/province [5]
0
0
Minnesota
Query!
Country [6]
0
0
United States of America
Query!
State/province [6]
0
0
New York
Query!
Country [7]
0
0
United States of America
Query!
State/province [7]
0
0
Ohio
Query!
Country [8]
0
0
United States of America
Query!
State/province [8]
0
0
Pennsylvania
Query!
Country [9]
0
0
United States of America
Query!
State/province [9]
0
0
Texas
Query!
Country [10]
0
0
United States of America
Query!
State/province [10]
0
0
Virginia
Query!
Country [11]
0
0
United States of America
Query!
State/province [11]
0
0
Washington
Query!
Country [12]
0
0
France
Query!
State/province [12]
0
0
Pierre-Bénite
Query!
Country [13]
0
0
France
Query!
State/province [13]
0
0
Rennes
Query!
Country [14]
0
0
France
Query!
State/province [14]
0
0
Toulouse
Query!
Country [15]
0
0
Spain
Query!
State/province [15]
0
0
Barcelona
Query!
Country [16]
0
0
Spain
Query!
State/province [16]
0
0
Salamanca
Query!
Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Query!
Name
Dren Bio
Query!
Address
Query!
Country
Query!
Other collaborator category [1]
0
0
Other
Query!
Name [1]
0
0
Novotech
Query!
Address [1]
0
0
Query!
Country [1]
0
0
Query!
Ethics approval
Ethics application status
Query!
Summary
Brief summary
This is a multicenter, first-in-human, Phase 1/2 study to evaluate the safety, tolerability,
pharmacokinetics, pharmacodynamics, and anti-tumor activity of DR-01 in adult patients with
large granular lymphocytic leukemia or cytotoxic lymphomas
Query!
Trial website
https://clinicaltrials.gov/ct2/show/NCT05475925
Query!
Trial related presentations / publications
Query!
Public notes
Query!
Contacts
Principal investigator
Name
0
0
Kimberley Dilley, MD, MPH
Query!
Address
0
0
Dren Bio
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for public queries
Name
0
0
Dren Central Contact
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
415-737-5277
Query!
Fax
0
0
Query!
Email
0
0
[email protected]
Query!
Contact person for scientific queries
Summary Results
For IPD and results data, please see
https://clinicaltrials.gov/ct2/show/NCT05475925
Download to PDF